Imax is a must for movie theaters, making the stock a buy, Morgan Stanley says

Morgan Stanley initiated IMAX at overweight with a $63 price target, implying 18% upside from Wednesday's close, citing a flywheel of expanding screens, releases, box-office revenue, earnings and free-cash-flow growth. The bank projects IMAX box office to rise to $1.7 billion in 2028 from $1.5 billion in 2026, supported by growing consumer demand for premium cinema experiences. IMAX shares have already gained more than 21% over the past three months, while 12 of 14 covering analysts rate the stock buy or strong buy.

Analysis

IMAX’s investable question is no longer whether premium-format demand exists, but whether the company can convert perceived scarcity into higher economics per screen without subsidizing exhibitor capex. Its licensing/royalty model gives incremental box-office growth unusually high flow-through versus theater operators such as AMC and CNK, while a broader premium mix can also improve exhibitors’ revenue per patron. The second-order beneficiary is DLB: theaters and studios investing behind premium audiovisual experiences may expand the addressable market for immersive formats, although Dolby Cinema remains IMAX’s clearest competitive substitute.

The near-term setup is less attractive than the fundamental narrative: a fresh bullish initiation against an already crowded buy-side consensus raises the probability that upside requires earnings-estimate revisions rather than another multiple expansion. Over the next 1-3 months, monitor premium-format share of opening-weekend receipts, announced system installations, and studio commitments to IMAX-native production. Over 6-18 months, the thesis depends on international screen growth—particularly China—and sustained tentpole supply; weaker theatrical slates would expose the operating leverage embedded in expectations.

Contrarian risk is that premium box office is event-driven rather than structurally durable. If studios reserve large-format releases for a limited number of franchise films, exhibitors may resist incremental installations or negotiate less favorable economics, limiting network flywheel benefits. A meaningful miss in installation backlog conversion, declining revenue per IMAX screen, or a weaker-than-expected 2027 slate would falsify the growth-duration case and likely compress the premium multiple quickly.

Key Decisions for Investors

• Maintain a tactical long IMAX only on post-initiation consolidation rather than chase momentum; target a 6-12 month horizon tied to installation and royalty estimate upgrades. Use a roughly 12-15% downside stop from entry or exit on evidence that per-screen box office is rolling over.
• Express the premium-format thesis as a pair: long IMAX / short AMC over 3-6 months. IMAX should retain better downside protection if attendance is merely flat because its economics are less exposed to theater-level fixed costs; the trade fails if broad attendance reaccelerates enough to drive high operating leverage at AMC.
• Watch DLB as a read-through and potential diversified alternative rather than a direct sympathy long. Initiate only if theater premium-format investment is corroborated by Dolby Cinema installation growth or management commentary; absent that data, competitive substitution risk makes the signal ambiguous.
• Do not buy upside calls after the analyst-driven move unless implied volatility remains below realized volatility and the next earnings date includes installation/backlog disclosure. The key catalyst is estimate revision, not the rating change itself; consensus positioning makes a modest execution miss disproportionately punitive.